NCT04698031Active, not recruitingPhase 4
Efficacy of Clopidogrel on Incidence of Silent Brain Infarction
Stroke and Coated-Platelets - A Translational Research Initiative
Source: ClinicalTrials.gov · Last updated 10 Aug 2026
Brief summary (registry, in English)
Silent brain infarctions (SBIs) are a manifestation of covert cerebrovascular disease, without obvious clinical deficit, noted very often in patients presenting with a new stroke or new transient ischemic attack. SBIs are linked to a significant increase in risk for subsequent stroke and cognitive decline. However, no biomarker is currently available that can predict the recurrence of these subclinical lesions. Coated-platelets are a measure of platelet procoagulant potential significantly increased in patients with ischemic stroke or transient ischemic attack compared to unaffected controls. Higher coated-platelet levels are strongly associated with both the presence and number of SBIs. Among medications approved for preventing stroke recurrence, the investigators identified clopidogrel as a pharmacological agent leading to a decrease in coated-platelet levels. In this project, the investigators plan to evaluate if clopidogrel can decrease the rate of occurrence of new silent brain infarctions. The result will enhance the investigators understanding of the relationship between platelets and silent brain infarcts, leading to improved health care delivery and also potential targets for novel preventive pharmacological interventions.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 134 (actual)
- First submitted
- 28 Dec 2020
- Start date
- 30 Mar 2022
- Primary completion date
- 1 May 2026
- Lead sponsor
- VA Office of Research and Development
- Diseases
- Stroke
- NCT number
- NCT04698031
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 134
- From 30 Mar 2022 to the primary completion date, 1 May 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- initiation of anticoagulation or thrombolytics prior to phlebotomy
- prior adverse/allergic reactions to clopidogrel
- treating physician deemed a different antiplatelet dose or dual antiplatelet therapy as the only treatment choice
Other illness
- dementia (based on chart review or self/proxy report)
- intracranial hemorrhage or bleeding diatheses
- end-stage renal disease (ESRD)
Other
- \> 90 days from onset of symptoms
- inability to tolerate consenting or phlebotomy
Who the study is looking for
- diagnosis of ischemic stroke/TIA
- \<90 days from onset of symptoms
- initial MRI available
- not receiving antiplatelet therapy at the time of admission
- medical decision by the treating physician that antiplatelet therapy is indicated for secondary prevention (decision independent of the study and based on individual clinical decision for each patient).
- baseline coated-platelet levels at 40%
- willingness to participate in the study for 24 months
Age in the registry: 21 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Oklahoma City VA Medical Center, Oklahoma City, OK Coordinator of this site? Confirm its status | Oklahoma City | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.